Retatrutide vs Ozempic vs Mounjaro: What’s the Difference?

What Is Retatrutide?

Retatrutide (LY3437943) is a synthetic triple incretin receptor agonist — a single peptide engineered to simultaneously activate GLP-1R, GIPR, and the glucagon receptor (GCGR). It is a 36-amino acid peptide with a C20 fatty diacid modification enabling albumin binding, with pharmacokinetics studied on a once-weekly schedule in preclinical study designs. As of 2026, retatrutide remains in clinical development and has not received FDA approval for any indication — research-grade material is the only form available for laboratory investigation. For the full mechanistic overview, see Retatrutide Research Overview.

Retatrutide Research Identity

The Three Receptors: What Each One Does

GLP-1 Receptor (GLP-1R) — Shared by All Three Compounds

GLP-1R is expressed in pancreatic beta cells, the CNS hypothalamus, the gastrointestinal tract, heart, and kidney. It’s the shared mechanistic foundation across semaglutide, tirzepatide, and retatrutide research — all three engage GLP-1R, which is why receptor-biology studies of all three examine glucose-dependent insulin secretion and satiety-circuit signaling as a baseline.

GIP Receptor (GIPR) — Added by Tirzepatide and Retatrutide

GIPR is expressed in pancreatic beta and alpha cells, adipose tissue, bone, the GI tract, and the CNS. GIP receptor activation engages complementary but mechanistically distinct signaling from GLP-1R — both are Gs-coupled, but their distinct intracellular signaling environments in shared cell types produce non-redundant research effects, particularly in adipose-tissue models.

Glucagon Receptor (GCGR) — Added Only by Retatrutide

GCGR is expressed in the liver, adipose tissue, heart, kidney, and brain. In isolation, glucagon receptor activation raises blood glucose via hepatic glycogenolysis and gluconeogenesis. In the context of simultaneous GLP-1R/GIPR agonism, GCGR activity is studied for its role in thermogenesis and hepatic fat oxidation — mechanisms not engaged by GLP-1R or GIPR alone. This is the core research rationale for the triple-agonist mechanism.

Mechanistic Scope: Receptor-Subtraction Research

Semaglutide functions as a single-receptor reference tool, isolating the GLP-1R-specific contribution to an observed effect. Tirzepatide adds GIPR, enabling comparison against semaglutide to isolate the GIPR contribution. Retatrutide adds GCGR, enabling comparison against tirzepatide to isolate the GCGR contribution. Together, the three compounds form a receptor-subtraction toolkit for systematically attributing research findings to specific receptor pathways — individually, in pairs, or all three combined.

These are laboratory research applications used to investigate receptor pharmacology and signaling mechanisms. Findings from in vitro, preclinical, or other laboratory research models do not establish a use, benefit, or outcome in humans or animals.

Regulatory & Research-Availability Status

Semaglutide (marketed as Ozempic, Wegovy, and Rybelsus) and tirzepatide (marketed as Mounjaro and Zepbound) are FDA-approved pharmaceutical products, manufactured under pharmaceutical GMP conditions for human patients under medical supervision. Retatrutide has no approved pharmaceutical equivalent — it exists only as a research compound. Research-grade Triple Regulator is not a version or alternative of any approved drug; it’s a laboratory reagent for in vitro and preclinical investigation of a mechanism with no marketed counterpart.

Triple Regulator (TIA-39-C20) is AminoForge’s catalog listing for this research compound — ≥99% purity by HPLC, independent third-party COA on every batch.

The Incretin Research Toolkit at AminoForge

AminoForge carries the full incretin receptor research toolkit, enabling systematic single-to-triple agonism research designs:

• Single Regulator (SIA-31-C18) — GLP-1R monoagonist. Available at AminoForge. See Semaglutide vs Ozempic vs Wegovy.
• Dual Regulator (DIA-39-C20) — GLP-1R + GIPR. Available at AminoForge. See Tirzepatide vs Mounjaro vs Zepbound.
• Triple Regulator (TIA-39-C20) — GLP-1R + GIPR + GCGR. Available at AminoForge.
• Amylin Analog (CAG-31-C18) — complementary amylin-receptor pathway. Available at AminoForge. See Cagrilintide Research Overview.

FAQ

Further Reading

• Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide (PubMed)

All products sold by AminoForge are intended exclusively for laboratory and research purposes. Not for human or veterinary consumption. Researchers are responsible for compliance with all applicable laws and regulations governing research compound use in their jurisdiction.